Company Overview
Company Type: Private Company
Website: ca.virogin.com
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 345.30
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Virogin Biotech Ltd. offers cancer therapeutics research and biological drug development with a focus on oncolytic viruses and immunotherapy. The company’s product includes VG161. Further, the company researches and develops oncolytic virotherapy technologies targeting multiple tumor types. Virogin Biotech Ltd. has a strategic collaboration partnership with Guangdong University of Technology. The company was founded in 2015 and is based in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Huang, Chris 
Co-Founder & CEO
Jia, Wei-Guo 
Co-Founder & Chief Scientific Officer
Lange, Jeffery 
Executive Vice President of Business Development
Rahimian, Shah 
Senior Vice President of Clinical Development & Medical Affairs
Zhao, Ronghua 
Chief Medical Officer


Primary Industry Classification
Biotechnology


Primary Office Location
408-3800 Wesbrook Mall | Vancouver, BC | V6S 2L9 | Canada

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
China Capital Management Co., Ltd.
Sep-24-2021
Unknown
-
Series D
China Life Private Equity Investment Co., Ltd.
Sep-24-2021
Unknown
-
Series D
GF Qianhe Investment Co., Ltd.
Sep-24-2021
Unknown
-
Series D
Linden Asset
Sep-24-2021
Unknown
-
Series D
Shenzhen Capital Group Co., Ltd.
Sep-24-2021
Unknown
-
Series D


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-24-2021
Sep-24-2021
Private Placement
Target
Virogin Biotech Ltd.
Shanghai Pan-Lin Asset Management Co., Ltd.,China Life Private Equity Investment Co., Ltd.,Shenzhen Capital Group Co., Ltd.,GF Qianhe Investment Co., Ltd.,China Capital Management Co., Ltd.,Linden Asset

120.00
May-07-2021
May-07-2021
Private Placement
Target
Virogin Biotech Ltd.
GP Capital Co., Ltd.,Shanghai Pan-Lin Asset Management Co., Ltd.,Chengtong Fund Management Co., Ltd.,Forebright Capital Management Limited Buyer Funds:China Structural Reform Fund Co., Ltd.

80.00
Sep-21-2020
Sep-21-2020
Private Placement
Target
Virogin Biotech Ltd.
CDH Investment Management Company Limited,Korea Investment Partners (Shanghai) Venture Capital Management Co., Ltd.,Shanghai Pan-Lin Asset Management Co., Ltd.,Linden Asset Management Inc.,State Development & Investment Corp., Ltd.,China Merchants Capital Investment Co., Ltd.

62.00
Dec-07-2018
Dec-07-2018
Private Placement
Target
Virogin Biotech Ltd.
Sinopharm Capital (nka:Shanghai Jianyi Private Equity Fund Management Co., Ltd.)

10.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-07-2022
Company Conference Presentations
Virogin Biotech Ltd. Presents at 7th Annual Oncolytic Virotherapy Summit, Dec-07-2022 01:30 PM
Nov-15-2022
Product-Related Announcements
Virogin Biotech Announces Dosing the First US Patient in A Phase 1 Study of VG201 for Patients with Advanced Solid Tumors
Sep-08-2022
Strategic Alliances
Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers
Oct-27-2021
Company Conference Presentations
Virogin Biotech Ltd. Presents at Oncolytic Virotherapy Summit, Oct-27-2021 02:50 PM
Sep-24-2021
Private Placements
Virogin Biotech Ltd. announced that it has received $120 million in funding from China Life Private Equity Investment Co., Ltd., Shenzhen Capital Group Co., Ltd., GF Qianhe Investment Co., Ltd., Shanghai Pan-Lin Asset Management Co., Ltd., China Capital Management Co., Ltd., Linden Asset


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 11:09 PM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Sep 14, 2023 09:24 PM
Virogin Biotech Ltd.
Virogin Biotech Ltd
Reports
55
GlobalData

Aug 29, 2023 01:52 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Jun 16, 2023 07:56 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd
Reports
54
GlobalData

Jun 09, 2023 02:11 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

May 17, 2023 05:37 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Mar 15, 2023 03:07 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd
Reports
54
GlobalData

Mar 10, 2023 12:43 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Feb 10, 2023 04:18 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Dec 14, 2022 03:53 AM
Virogin Biotech Ltd.
Virogin Biotech Ltd
Reports
56


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Huang, Chris 
Co-Founder & CEO
-
-
chrishuang@virogin.com
Jia, Wei-Guo 
Co-Founder & Chief Scientific Officer
-
-
wjia@virogin.com
Lange, Jeffery 
Executive Vice President of Business Development
-
-

Rahimian, Shah 
Senior Vice President of Clinical Development & Medical Affairs
-
-

Zhao, Ronghua 
Chief Medical Officer
-
-
rzhao@virogin.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
